Conference Highlights.
| Autor: | BRODERICK, JASON M., CLARKE, HANNAH, KAHL, KRISTIE L. |
|---|---|
| Předmět: |
THERAPEUTIC use of antineoplastic agents
THERAPEUTIC use of monoclonal antibodies SERIAL publications CASTRATION-resistant prostate cancer BLADDER tumors PAIN measurement PROSTATE-specific antigen PATIENT safety CONFERENCES & conventions CANCER chemotherapy CANCER pain DRUG efficacy QUALITY of life PROGRESSION-free survival HEALTH outcome assessment |
| Zdroj: | Urology Times; Jul2024, Vol. 52 Issue 7, p14-17, 4p |
| Abstrakt: | The article discusses the highlights of the American Society of Clinical Oncology annual meeting in May-June 2024. Topics covered include results showing darolutamide efficacy in nonmetastatic castration-resistant prostate cancer (nmCRPC), and patient-reported outcomes' (PRO) affirmation of efficacy data from EV-302 trial in urothelial cancer. Also noted is the absence of quality of life (QOL) impact in treatment suspension of enzalutamide on nonmetastatic hormone-sensitive prostate cancer. |
| Databáze: | Complementary Index |
| Externí odkaz: |
|